ABI-aftercare in Motion: Multidisciplinary Aftercare in the Home Environment in Patients With Acquired Brain Injury
Launched by MAJANKA H. HEIJENBROK-KAL, PHD · Sep 21, 2023
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
The ABI-aftercare in Motion study is exploring a new program designed to help people who have suffered an acquired brain injury (ABI) improve their recovery after outpatient rehabilitation. The program, called ABI-motion, aims to encourage a more active lifestyle and reduce ongoing health issues, ultimately leading to a better quality of life. The main goals of the study are to see if the ABI-motion program is practical for patients and to understand the health benefits it may provide.
To participate in this study, individuals need to be diagnosed with an acquired brain injury and currently undergoing outpatient rehabilitation at Rijndam Rehabilitation. Participants will receive educational support about their brain injury and engage in therapy sessions with movement specialists. After completing their rehabilitation, they will continue to receive support from a community buddy and follow-up care from a rehabilitation doctor. This study is open to all adults aged 65-74 who meet the eligibility criteria, as long as they can safely participate in moderate to vigorous exercise.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed with ABI
- • Follows an outpatient rehabilitation program for ABI in Rijndam Rehabilitation
- Exclusion Criteria:
- • Having a contra-indication for participation in moderate to vigorous exercise
- • Life expectancy \< 1 year
- • Incapacitated persons
About Majanka H. Heijenbrok Kal, Phd
Majanka H. Heijenbrok-Kal, PhD, is a distinguished clinical trial sponsor with extensive expertise in the design, implementation, and management of clinical research studies. With a strong background in biomedical sciences and a commitment to advancing healthcare, Dr. Heijenbrok-Kal leads initiatives that prioritize patient safety and ethical standards. Her innovative approach fosters collaboration among multidisciplinary teams, ensuring rigorous methodologies and compliance with regulatory requirements. Dr. Heijenbrok-Kal's dedication to scientific excellence and patient-centered research positions her as a key contributor to the advancement of medical knowledge and therapeutic development.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rotterdam, , Netherlands
Patients applied
Trial Officials
Gerard M Ribbers, MD, PhD
Study Chair
Erasmus Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported